국소 약물 전달 시장 : 2027 년까지의 세계 예측

출판 : MarketsandMarkets(마켓츠앤드마켓츠)출판년월 : 2022년05월

국소 약물 전달 시장 : 유형[반고체(크림, 젤, 로션), 고체(좌제), 액체(용액), 경피제품], 경로(피부, 안과), 사용시설(재택의료시설, 병원, 화상처리센터) – 2027 년까지의 세계 예측

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

페이지수 297
도표수 284
구성 영문조사보고서
가격

리포트목차    주문/문의    납기/라이센스안내

Sample Request

The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods.
글로벌 국소 약물 전달 시장은 2022년 2,074억 달러에서 2027년 3,178억 달러로 CAGR 8.9%로 성장할 것으로 예상됩니다. 이 시장의 성장은 주로 안구 건조증에 대한 국소 처방 요법의 높은 보급률, 스마트 경피 약물 전달 시스템의 R&D에 대한 제약 회사의 관심 증가, 중추 신경계 장애의 유병률 증가, 비약물에 대한 선호도 증가에 기인할 수 있습니다. 침습적 약물 전달 방법.

“The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.”
Based on products, the topical drug delivery the market is segmented into semi-solid formulations, liquid formulations, solid formulations, and transdermal products. The large share of semi-solid formulations segment is attributed to better patient adherence with limited side effects, more absorption, provide efficiency in drug release, and does not harm the gastrointestinal tract.

“Dermal drug delivery accounted for the largest share of the market.”
Based on the route of administration, the market is segmented into dermal, ophthalmic, rectal, vaginal, and nasal drug delivery. The large share of the dermal drug delivery market segment can largely be attributed to accessible product launches and adoption as they have fewer regulatory requirements, enhancement of penetrations and permeation of drugs as they are delivered through skin, and less irritation in patients as compared to nasal or ophthalmic drug delivery.

“Home care settings hold the largest share in the market, by facility of use”
Based on the facility of use, the market is segmented into home care settings, hospitals & clinics, burn centers, and other facilities. The large share of home care settings segment can be attributed to better patient comfort, growing awareness regarding home care settings is improving patient acceptability, decline in hospital visits due to COVID-19 pandemic, and shift in trend from treatments carried out in hospitals and nursing homes to treatments at home due to cost-effectiveness of home care settings.

“The APAC to witness the highest growth during the forecast period.”
Asia Pacific is expected to grow at the highest CAGR during the forecast period of 2022–2027. The high incidence of skin diseases (such as skin cancer), the rising prevalence of chronic diseases (such as diabetes), increasing use of contraceptives, the increasing geriatric population, and the growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems are some of the major factors that are expected to drive the growth of the topical drug delivery market in the Asia Pacific region.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–35%, Tier 2–45%, and Tier 3–20%
• By Designation – C-level–35%, Director-level–25%, Others–40%
• By Region – North America–45%, Europe–30%, Asia Pacific–20%, Latin America- 3%, Middle East and Africa–2%

Key players in the Topical Drug Delivery Market

The prominent players in the topical drug delivery market are Glenmark Pharmaceuticals Ltd. (India), Galderma (Switzerland), Johnson & Johnson Private Limited (US), GlaxoSmithKline Plc. (UK), Bausch Health Companies Inc. (Canada), Hisamitsu Pharmaceuticals Inc. (Japan), Cipla (India), Bayer AG (Germany), Viatris Inc. (Mylan N.V.) (US), 3M (US), Merck & Co.Inc.. (Germany), Crescita Therpeautics Inc. (Canada), Novartis International AG (Switzerland), Boehringer Ingelheim International GmBH (Germany), Pfizer Inc. (US), Teva Pharmaceuticals Industries Ltd. (Israel), Bristol Myers Squibb (US), Lead Chemical Co., Ltd. (Japan), Purdue Pharma L.P. (US), Lavipharm (Greece), AbbVie Inc. (US), CMP Pharma, Inc. (Germany), Encore Dermatology, Inc. (US), Prosolus Inc. (US), and Rusan Pharma Ltd. (India).

Research Coverage:
The report analyzes the topical drug delivery market and aims at estimating the market size and future growth potential of this market based on various segments such as product, route of administration, facility of use, and region. The report also includes a product portfolio matrix of various topical drug delivery products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the topical drug delivery market. The report analyzes this market by product, by route of administration, and by facility of use.
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global topical drug delivery market
• Market Development: Comprehensive information on the lucrative emerging markets by product, route of administration, and facility of use
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global topical drug delivery market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global topical drug delivery market.


목차

TABLE OF CONTENTS

1 INTRODUCTION (Page No. – 36)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION AND SCOPE
1.2.1 INCLUSIONS & EXCLUSIONS
1.2.2 MARKETS COVERED
FIGURE 1 TOPICAL DRUG DELIVERY MARKET SEGMENTATION
1.2.3 YEARS CONSIDERED
1.3 CURRENCY
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. – 40)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE PARTICIPANTS
2.2 MARKET SIZE ESTIMATION
FIGURE 6 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS
FIGURE 7 TOPICAL DRUG DELIVERY MARKET – REVENUE SHARE ANALYSIS ILLUSTRATION: JOHNSON & JOHNSON
FIGURE 8 PHARMACEUTICAL SALES APPROACH
FIGURE 9 TOP-DOWN APPROACH
FIGURE 10 CAGR PROJECTIONS
FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN TOPICAL DRUG DELIVERY MARKET (2022–2027): IMPACT ON MARKET GROWTH & CAGR
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 12 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.6.2 SCOPE-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
TABLE 2 RISK ASSESSMENT: TOPICAL DRUG DELIVERY MARKET

3 EXECUTIVE SUMMARY (Page No. – 54)
FIGURE 13 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022 VS. 2027 (USD BILLION)
FIGURE 14 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022 VS. 2027 (USD BILLION)
FIGURE 15 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022 VS. 2027 (USD BILLION)
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF TOPICAL DRUG DELIVERY MARKET

4 PREMIUM INSIGHTS (Page No. – 58)
4.1 TOPICAL DRUG DELIVERY MARKET OVERVIEW
FIGURE 17 HIGH PREVALENCE OF SKIN DISEASES AND HIGH INCIDENCE OF BURN INJURIES TO DRIVE MARKET GROWTH
4.2 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT AND COUNTRY (2021)
FIGURE 18 SEMI-SOLID FORMULATIONS TO DOMINATE LATIN AMERICA MARKET IN 2021
4.3 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 19 INDIA TO REGISTER HIGHEST GROWTH IN MARKET DURING FORECAST PERIOD
4.4 TOPICAL DRUG DELIVERY MARKET, BY REGION (2020–2027)
FIGURE 20 NORTH AMERICA TO DOMINATE MARKET IN 2027
4.5 TOPICAL DRUG DELIVERY MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. – 62)
5.1 INTRODUCTION
5.2 PRICING ANALYSIS
TABLE 3 TOPICAL DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 High prevalence of skin diseases
5.2.1.2 Increase in self-medication as a popular practice in dermatology
5.2.1.3 High prevalence of topical prescription therapy for dry eye diseases
5.2.1.4 Switching from conventional needle injections to transdermal patches
5.2.1.5 High incidence of burn injuries
5.2.1.6 Growing prevalence of diabetes
5.2.2 RESTRAINTS
5.2.2.1 Continuous irritation of skin and allergies caused by topical drugs
5.2.2.2 Preference for alternative modes of drug delivery
5.2.3 OPPORTUNITIES
5.2.3.1 Rising demand for self-administration and home care
5.2.3.2 Delivery of biologics through transdermal route
5.2.3.3 Topical vehicles used in cosmetic industry
5.2.4 CHALLENGES
5.2.4.1 Topical formulations for drugs with limited plasma concentration
5.2.4.2 Increasing number of drug failures and product recalls
5.3 PORTER’S FIVE FORCES ANALYSIS
5.3.1 NEW ADVANCEMENT IN TRANSDERMAL DRUG DELIVERY SYSTEM
5.3.2 ADOPTION OF TELEDERMATOLOGY
5.4 PATENT ANALYSIS
TABLE 4 TOPICAL DRUG DELIVERY MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.5 MARKET DYNAMICS
5.6 INDUSTRY TRENDS
TABLE 5 REGULATORY SCENARIO, BY COUNTRY
5.7 KEY CONFERENCES & EVENTS IN 2022-2023
FIGURE 22 TOPICAL DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS
5.8 IMPACT OF COVID-19
FIGURE 23 PHARMACEUTICAL DRUG DELIVERY MARKET ECOSYSTEM
5.9 REGULATORY ANALYSIS
5.10 VALUE CHAIN ANALYSIS
TABLE 6 REGIONAL PRICING ANALYSIS OF TOPICAL DRUGS, 2021 (USD)
5.11 ECOSYSTEM MAPPING
TABLE 7 TOPICAL DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS
5.11.1 THREAT OF NEW ENTRANTS
5.11.2 THREAT OF SUBSTITUTES
5.11.3 BARGAINING POWER OF SUPPLIERS
5.11.4 BARGAINING POWER OF BUYERS
5.11.5 INTENSITY OF COMPETITIVE RIVALRY
5.12 TECHNOLOGY ANALYSIS
5.12.1 PATENT PUBLICATION TRENDS FOR TOPICAL DRUG DELIVERY
FIGURE 24 PATENT PUBLICATION TRENDS (JANUARY 2011– APRIL 2022)
5.12.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
FIGURE 25 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR TOPICAL DRUG DELIVERY PATENTS (JANUARY 2011–APRIL 2022)
FIGURE 26 TOP APPLICANT COUNTRIES/REGIONS FOR TOPICAL DRUG DELIVERY (JANUARY 2011–APRIL 2022)
TABLE 8 LIST OF PATENTS/PATENT APPLICATIONS IN TOPICAL DRUG DELIVERY MARKET, 2021–2022

6 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT (Page No. – 84)
6.1 INTRODUCTION
TABLE 9 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
6.2 SEMI-SOLID FORMULATIONS
TABLE 10 KEY TOPICAL DRUG DELIVERY SEMI-SOLID FORMULATIONS AVAILABLE
TABLE 11 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 12 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY COUNTRY, 2020–2027 (USD BILLION)
6.2.1 OINTMENTS
6.2.1.1 Ointments to be widely used in analgesic indications
TABLE 13 TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY COUNTRY, 2020–2027 (USD BILLION)
6.2.2 CREAMS
6.2.2.1 Creams to be most widely used formulation due to better absorption
TABLE 14 TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY COUNTRY, 2020–2027 (USD BILLION)
6.2.3 LOTIONS
6.2.3.1 Easy administration of lotions to drive demand
TABLE 15 TOPICAL DRUG DELIVERY MARKET FOR LOTIONS, BY COUNTRY, 2020–2027 (USD BILLION)
6.2.4 GELS
6.2.4.1 Faster drug release and greater patient acceptability to drive gels market
TABLE 16 TOPICAL DRUG DELIVERY MARKET FOR GELS, BY COUNTRY, 2020–2027 (USD BILLION)
6.2.5 PASTES
6.2.5.1 Topical pastes to treat and prevent skin irritation
TABLE 17 TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY COUNTRY, 2020–2027 (USD BILLION)
6.3 LIQUID FORMULATIONS
TABLE 18 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 19 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2020–2027 (USD BILLION)
TABLE 20 KEY LIQUID FORMULATIONS AVAILABLE
6.3.1 SUSPENSIONS
6.3.1.1 Higher rate of bioavailability and controlled onset of action to support market growth
TABLE 21 TOPICAL DRUG DELIVERY MARKET FOR SUSPENSIONS, BY COUNTRY, 2020–2027 (USD BILLION)
6.3.2 SOLUTIONS
6.3.2.1 Topical solutions with soluble chemicals to dissolve in various solvents
TABLE 22 TOPICAL DRUG DELIVERY MARKET FOR SOLUTIONS, BY COUNTRY, 2020–2027 (USD BILLION)
6.4 SOLID FORMULATIONS
TABLE 23 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 24 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2020–2027 (USD BILLION)
TABLE 25 KEY SOLID FORMULATIONS AVAILABLE
6.4.1 POWDERS
6.4.1.1 Inexpensive manufacturing and effectiveness against antifungal infections to propel powders market
TABLE 26 TOPICAL DRUG DELIVERY MARKET FOR POWDERS, BY COUNTRY, 2020–2027 (USD BILLION)
6.4.2 SUPPOSITORIES
6.4.2.1 Suppositories require suitable base to ensure drug compatibility and stability
TABLE 27 TOPICAL DRUG DELIVERY MARKET FOR SUPPOSITORIES , BY COUNTRY, 2020–2027 (USD BILLION)
6.5 TRANSDERMAL PRODUCTS
TABLE 28 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 29 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2020–2027 (USD BILLION)
TABLE 30 KEY TRANSDERMAL PRODUCTS AVAILABLE
6.5.1 TRANSDERMAL PATCHES
6.5.1.1 Transdermal patches to offer increased drug permeability across skin
TABLE 31 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY COUNTRY, 2020–2027 (USD BILLION)
6.5.2 TRANSDERMAL SEMI-SOLIDS
6.5.2.1 Transdermal semi-solids to offer fast drying on application site
TABLE 32 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL SEMI-SOLIDS, BY COUNTRY, 2020–2027 (USD BILLION)

7 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION (Page No. – 107)
7.1 INTRODUCTION
TABLE 33 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
7.2 DERMAL DRUG DELIVERY
7.2.1 NANO-SIZED DRUG CARRIER SYSTEMS TO BE STUDIED TO OVERCOME DRUG PENETRATION LIMITATION
TABLE 34 DERMAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
7.3 OPHTHALMIC DRUG DELIVERY
7.3.1 MICROEMULSION-BASED FORMULATIONS LEAD TO BETTER OCULAR DRUG ADSORPTION
TABLE 35 OPHTHALMIC DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
7.4 VAGINAL DRUG DELIVERY
7.4.1 RICH AND COMPLEX NETWORK OF CAPILLARIES OF UPPER VAGINA TO CREATE SYSTEMIC DRUG DELIVERY SYSTEM
TABLE 36 VAGINAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
7.5 RECTAL DRUG DELIVERY
7.5.1 RECTAL ADMINISTRATION TO ENABLE BOTH LOCAL AND SYSTEMIC THERAPY OF DRUGS
TABLE 37 RECTAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
7.6 NASAL DRUG DELIVERY
7.6.1 NASAL DELIVERY ROUTE OFFERS QUICK ONSET OF DRUG ACTION AND CONVENIENCE AS COMPARED TO PARENTERAL ROUTE
TABLE 38 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION)

8 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE (Page No. – 118)
8.1 INTRODUCTION
TABLE 39 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
8.2 HOMECARE SETTINGS
8.2.1 HOMECARE TO DOMINATE MARKET DURING FORECAST PERIOD
TABLE 40 TOPICAL DRUG DELIVERY MARKET FOR HOMECARE SETTINGS, BY COUNTRY, 2020–2027 (USD BILLION)
8.3 HOSPITALS & CLINICS
8.3.1 TOPICAL ANAESTHETICS TO BE ADOPTED FOR VARIOUS MEDICAL AND SURGICAL SUB-SPECIALTIES
TABLE 41 TOPICAL DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD BILLION)
8.4 BURN CENTERS
8.4.1 TOPICAL ANTIMICROBIAL FORMULATIONS FOR BURN-RELATED INJURIES TO DRIVE MARKET GROWTH
TABLE 42 TOPICAL DRUG DELIVERY MARKET FOR BURN CENTERS, BY COUNTRY, 2020–2027 (USD BILLION)
8.5 OTHER FACILITIES
TABLE 43 TOPICAL DRUG DELIVERY MARKET FOR OTHER FACILITIES, BY COUNTRY, 2020–2027 (USD BILLION)

9 TOPICAL DRUG DELIVERY MARKET, BY REGION (Page No. – 126)
9.1 INTRODUCTION
FIGURE 27 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
TABLE 44 TOPICAL DRUG DELIVERY MARKET, BY REGION, 2020–2027 (USD BILLION)
9.2 NORTH AMERICA
FIGURE 28 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
TABLE 45 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
TABLE 46 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 47 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 48 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 49 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 50 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 51 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
TABLE 52 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
9.2.1 US
9.2.1.1 Rising prevalence of skin diseases alongside approval and launch of innovative topical formulations to propel market growth
TABLE 53 US: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 54 US: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 55 US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 56 US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 57 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 58 US: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
TABLE 59 US: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
9.2.2 CANADA
9.2.2.1 Rising prevalence of hypertension and funding for topical drugs research to drive market growth
TABLE 60 CANADA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 61 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 62 CANADA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 63 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 64 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 65 CANADA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
TABLE 66 CANADA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
9.3 EUROPE
TABLE 67 RECENT DEVELOPMENTS IN EUROPEAN TOPICAL DRUG DELIVERY MARKET, 2019–2022
TABLE 68 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
TABLE 69 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 70 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 71 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 72 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 73 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 74 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
TABLE 75 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
9.3.1 GERMANY
9.3.1.1 Growing focus of pharmaceutical companies on topical products development and increasing target diseases to drive market growth
TABLE 76 DEVELOPMENTS AND PRODUCT LAUNCHES IN TOPICAL DRUG DELIVERY IN GERMANY, 2019–2022
TABLE 77 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 78 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 79 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 80 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 81 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 82 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
TABLE 83 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
9.3.2 UK
9.3.2.1 Increasing developments by top players and demand for pain-free treatment to drive market growth
TABLE 84 UK: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 85 UK: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 86 UK: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 87 UK: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 88 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 89 UK: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
TABLE 90 UK: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
9.3.3 FRANCE
9.3.3.1 Rising prevalence of diabetes and increasing geriatric population to support market growth
TABLE 91 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 92 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 93 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 94 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 95 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 96 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
TABLE 97 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
9.3.4 ITALY
9.3.4.1 Rising number of smokers to propel transdermal patches demand
TABLE 98 ITALY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 99 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 100 ITALY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 101 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 102 ITALY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 103 ITALY: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
TABLE 104 ITALY: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
9.3.5 SPAIN
9.3.5.1 Growing diabetic patients to drive market growth
TABLE 105 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 106 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 107 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 108 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 109 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 110 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
TABLE 111 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
9.3.6 SWITZERLAND
9.3.6.1 Rising geriatric population and emerging players focusing on topical drugs development to drive market growth
TABLE 112 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 113 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 114 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 115 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 116 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 117 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
TABLE 118 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
9.3.7 REST OF EUROPE
TABLE 119 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 120 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 121 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 122 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 123 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 124 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
TABLE 125 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
9.4 ASIA PACIFIC
FIGURE 29 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
TABLE 126 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
TABLE 127 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 128 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION)
TABLE 129 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 130 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 131 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 132 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
TABLE 133 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
9.4.1 CHINA
9.4.1.1 Prevalence of diabetes and increase in pharmaceutical R&D investments to drive market growth
TABLE 134 CHINA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 135 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION)
TABLE 136 CHINA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 137 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 138 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 139 CHINA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
TABLE 140 CHINA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
9.4.2 JAPAN
9.4.2.1 Increasing number of product approvals and growing focus of local players on topical formulations R&D to support market growth
TABLE 141 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 142 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION)
TABLE 143 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 144 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 145 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 146 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
TABLE 147 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
9.4.3 INDIA
9.4.3.1 Rising awareness among healthcare providers and patients alongside increasing focus on noninvasive methods of drug delivery to drive market growth
TABLE 148 INDIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 149 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION)
TABLE 150 INDIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 151 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 152 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 153 INDIA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
TABLE 154 INDIA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
9.4.4 AUSTRALIA
9.4.4.1 Increasing number of smokers to drive market growth
TABLE 155 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 156 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 157 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 158 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 159 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 160 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
TABLE 161 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
9.4.5 REST OF ASIA PACIFIC
TABLE 162 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 163 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 164 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 165 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 166 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 167 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
TABLE 168 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
9.5 LATIN AMERICA
TABLE 169 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2027 (USD BILLION)
TABLE 170 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 171 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION)
TABLE 172 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 173 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 174 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 175 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
TABLE 176 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
9.5.1 BRAZIL
9.5.1.1 High prevalence of diabetes to propel market growth
TABLE 177 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 178 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION)
TABLE 179 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 180 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 181 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 182 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
TABLE 183 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
9.5.2 MEXICO
9.5.2.1 Increasing prevalence of glaucoma to drive market growth
TABLE 184 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 185 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION)
TABLE 186 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 187 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 188 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 189 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
TABLE 190 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
9.5.3 REST OF LATIN AMERICA
TABLE 191 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 192 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 193 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 194 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 195 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 196 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
TABLE 197 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)
9.6 MIDDLE EAST & AFRICA
9.6.1 GROWING PREVALENCE OF BURN INJURIES AND INCREASING EXPENDITURE ON HEALTHCARE TO DRIVE MARKET GROWTH
TABLE 198 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2027 (USD BILLION)
TABLE 199 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2020–2027 (USD BILLION)
TABLE 200 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 201 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2027 (USD BILLION)
TABLE 202 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 203 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD BILLION)
TABLE 204 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2027 (USD BILLION)

10 COMPETITIVE LANDSCAPE (Page No. – 204)
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS
10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 30 REVENUE ANALYSIS OF TOP PLAYERS IN TOPICAL DRUG DELIVERY MARKET
10.4 MARKET SHARE ANALYSIS
FIGURE 31 TOPICAL DRUG DELIVERY MARKET SHARE, BY KEY PLAYER, 2021
TABLE 205 TOPICAL DRUG DELIVERY MARKET: DEGREE OF COMPETITION
10.5 COMPETITIVE LEADERSHIP MAPPING
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
FIGURE 32 TOPICAL DRUG DELIVERY MARKET: COMPETITIVE LEADERSHIP MAPPING (2021)
10.6 COMPETITIVE LEADERSHIP MAPPING FOR OTHER PLAYERS
10.6.1 PROGRESSIVE COMPANIES
10.6.2 DYNAMIC COMPANIES
10.6.3 STARTING BLOCKS
10.6.4 RESPONSIVE COMPANIES
FIGURE 33 TOPICAL DRUG DELIVERY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR OTHER PLAYERS (2021)
10.7 COMPANY FOOTPRINT
TABLE 206 COMPANY FOOTPRINT: TOPICAL DRUG DELIVERY MARKET
10.7.1 PRODUCT FOOTPRINT OF MAJOR PLAYERS
TABLE 207 PRODUCT FOOTPRINT: TOPICAL DRUG DELIVERY MARKET (2021)
10.7.2 ROUTE OF ADMINISTRATION FOOTPRINT OF TOPICAL DRUG DELIVERY MARKET
TABLE 208 ROUTE OF ADMINISTRATION FOOTPRINT: TOPICAL DRUG DELIVERY MARKET (2021)
10.7.3 FACILITY OF USE IN TOPICAL DRUG DELIVERY MARKET
TABLE 209 FACILITY OF USE FOOTPRINT: TOPICAL DRUG DELIVERY MARKET (2021)
10.7.4 GEOGRAPHIC FOOTPRINT OF MAJOR PLAYERS IN TOPICAL DRUG DELIVERY MARKET
TABLE 210 GEOGRAPHIC FOOTPRINT: TOPICAL DRUG DELIVERY MARKET (2021)
10.8 COMPETITIVE SCENARIO
10.8.1 PRODUCT LAUNCHES
TABLE 211 PRODUCT LAUNCHES, JANUARY 2019–APRIL 2022
10.8.2 DEALS
TABLE 212 DEALS, JANUARY 2019–APRIL 2022
10.8.3 OTHER DEVELOPMENTS
TABLE 213 OTHER DEVELOPMENTS, JANUARY 2019–APRIL 2022

11 COMPANY PROFILES (Page No. – 222)
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1 KEY PLAYERS
11.2 OTHER PLAYERS
11.1.1 GLENMARK PHARMACEUTICALS LTD.
TABLE 214 GLENMARK PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
FIGURE 34 GLENMARK PHARMACEUTICALS LTD.: COMPANY SNAPSHOT (2021)
11.1.2 GALDERMA
TABLE 215 GALDERMA: BUSINESS OVERVIEW
11.1.3 JOHNSON & JOHNSON PRIVATE LIMITED
TABLE 216 JOHNSON & JOHNSON PRIVATE LIMITED: BUSINESS OVERVIEW
FIGURE 35 JOHNSON & JOHNSON PRIVATE LIMITED: COMPANY SNAPSHOT (2021)
11.1.4 GLAXOSMITHKLINE PLC.
TABLE 217 GLAXOSMITHKLINE PLC: BUSINESS OVERVIEW
FIGURE 36 GLAXOSMITHKLINE, PLC.: COMPANY SNAPSHOT (2021)
11.1.5 BAUSCH HEALTH COMPANIES INC.
TABLE 218 BAUSCH HEALTH COMPANIES INC.: BUSINESS OVERVIEW
FIGURE 37 BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT (2021)
11.1.6 HISAMITSU PHARMACEUTICAL CO., INC.
TABLE 219 HISAMITSU PHARMACEUTICAL CO., INC.: BUSINESS OVERVIEW
FIGURE 38 HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY SNAPSHOT (2021)
11.1.7 CIPLA
TABLE 220 CIPLA: BUSINESS OVERVIEW
FIGURE 39 CIPLA: COMPANY SNAPSHOT (2021)
11.1.8 BAYER AG
TABLE 221 BAYER AG: BUSINESS OVERVIEW
FIGURE 40 BAYER AG: COMPANY SNAPSHOT (2021)
11.1.9 VIATRIS INC. (MYLAN N.V.)
TABLE 222 VIATRIS INC.: BUSINESS OVERVIEW
FIGURE 41 VIATRIS INC.: COMPANY SNAPSHOT (2021)
11.1.10 3M
TABLE 223 3M: BUSINESS OVERVIEW
FIGURE 42 3M: COMPANY SNAPSHOT (2021)
11.1.11 MERCK & CO., INC.
TABLE 224 MERCK & CO., INC.: BUSINESS OVERVIEW
FIGURE 43 MERCK & CO., INC.: COMPANY SNAPSHOT (2021)
11.1.12 CRESCITA THERAPEUTICS INC.
TABLE 225 CRESCITA THERAPEUTICS INC.: BUSINESS OVERVIEW
FIGURE 44 CRESCITA THERAPEUTICS INC.: COMPANY SNAPSHOT (2021)
11.1.13 NOVARTIS INTERNATIONAL AG
TABLE 226 NOVARTIS INTERNATIONAL: BUSINESS OVERVIEW
FIGURE 45 NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT (2021)
11.1.14 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
TABLE 227 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW
FIGURE 46 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2021)
11.1.15 PFIZER INC.
TABLE 228 PFIZER INC.: BUSINESS OVERVIEW
FIGURE 47 PFIZER INC.: COMPANY SNAPSHOT (2021)
11.1.16 TEVA PHARMACEUTICAL INDUSTRIES LTD.
TABLE 229 TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW
FIGURE 48 TEVA PHARMACEUTICALS: COMPANY SNAPSHOT (2021)
11.1.17 BRISTOL MYERS SQUIBB
TABLE 230 BRISTOL MYERS SQUIBB: BUSINESS OVERVIEW
FIGURE 49 BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT (2021)
11.1.18 LEAD CHEMICAL CO., LTD.
TABLE 231 LEAD CHEMICAL CO., LTD.: BUSINESS OVERVIEW
11.1.19 PURDUE PHARMA L.P.
TABLE 232 PURDUE PHARMA L.P.: BUSINESS OVERVIEW
11.1.20 LAVIPHARM
TABLE 233 LAVIPHARM: BUSINESS OVERVIEW
11.1.21 ABBVIE INC.
TABLE 234 ABBVIE INC.: BUSINESS OVERVIEW
FIGURE 50 ABBVIE INC.: COMPANY SNAPSHOT (2021)
12.1 INSIGHTS FROM INDUSTRY EXPERTS
11.2.1 CMP PHARMA, INC.
11.2.2 ENCORE DERMATOLOGY, INC.
11.2.3 PROSOLUS INC.
11.2.4 RUSAN PHARMA LTD.
12.2 DISCUSSION GUIDE
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12 APPENDIX (Page No. – 298)
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.4 AVAILABLE CUSTOMIZATIONS
12.5 RELATED REPORTS
12.6 AUTHOR DETAILS


    • 리포트 제목은 자동으로 입력됩니다.
    • *항목은 필수항목입니다.

    의뢰분류*

    성함*

    회사명*

    부서명

    이메일*

    전화번호

    저희 사이트를 알게 된 경로를 가르쳐 주세요.

    문의 내용*

     

    ※개인정보보호정책은여기에서 확인 가능합니다。

    Email 문의도 받고 있습니다.
    아래 주소이며 죄송하지만 "(at)"을 "@"로 바꾸어 보내주시길 부탁드립니다.
    mooneui(at)chosareport-korea.com